InterAct Therapeutics

InterAct Therapeutics is a Nashville-based biotechnology company dedicated to discovering and developing small molecule inhibitors of protein-protein interactions (PPIs) for the treatment of cancer. The company was founded through a collaboration between Vanderbilt University and Deerfield Management to commercialize the pioneering research of Dr. Stephen Fesik. Its lead program focuses on disrupting the interaction between the MYC oncoprotein and its essential cofactor, WDR5, a strategy designed to inhibit MYC-driven tumor growth. InterAct leverages a structure-based drug discovery approach to target high-value, historically "undruggable" oncogenic drivers. By focusing on specific PPI interfaces, the company aims to create highly selective therapies for aggressive solid tumors and leukemias.